Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. Please see detailed guidance ...
The Novartis HIT team is composed of experienced technical subject matter experts. These informaticists specialize in patient-centered care and HIT optimization coordination. The HIT Team can offer ...
. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
About Novartis in Cardiovascular Disease At Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud ...
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings ...
Having elevated levels of lipoprotein (a), or Lp (a) for short, increases a person’s chances of having a cardiovascular event such as a stroke or a heart attack. It was after having two heart attacks ...
Behind every transformational leader is a remarkable story. For Reshema Kemps-Polanco, Chief Commercial Officer of Novartis US, it's a journey that weaves together military discipline, a sharp ...
Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused ...
At Novartis, we reimagine medicine to improve and extend people’s lives. This includes discovering and developing breakthrough therapies and finding new ways to deliver these treatments to as many ...
Bryan Laffitte has had a long career at Novartis in San Diego, California—with some twists and turns. After spending thirteen years at Novartis in a variety of roles, he explored opportunities in ...
One of the secrets to living a longer, better life is beating in our chests. An estimated 80% of cardiovascular disease (CVD) can be prevented with lifestyle changes and available tools, yet it ...
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results